These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19744017)

  • 1. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour lysis syndrome with acute renal failure during imatinib therapy.
    Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
    Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    Fran├žois H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 8. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
    Wong M; Sade S; Gilbert M; Klieb HB
    Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
    Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
    Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adverse effects of imatinib mesylate].
    Isshiki I
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
    [No Abstract]   [Full Text] [Related]  

  • 13. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Busuttil DP
    Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
    Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
    Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome?
    Basturk A; Hacibekiroglu T; Akinci S; Dilek I; Atalay HV
    Ren Fail; 2011; 33(4):465. PubMed ID: 21529279
    [No Abstract]   [Full Text] [Related]  

  • 17. Irreversible sensorineural hearing loss due to Imatinib.
    Attili VS; Bapsy PP; Anupama G; Lokanatha D
    Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
    Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.